上海柯君医药科技

Kernal Biopharma is a clinical-stage biopharmaceutical company headquartered in Shanghai, China, specializing in the discovery and development of innovative small molecule drugs. The company utilizes a proprietary structure-based drug design platform to address significant unmet medical needs in the fields of infectious diseases and neurology. Its lead candidate, KJ-03, is a 3C-like protease inhibitor developed for the treatment of COVID-19, while KJ-01 targets chronic Hepatitis B through capsid assembly modulation. Additionally, the company is advancing a pipeline of neurodegenerative treatments, including a LRRK2 inhibitor for Parkinson's disease. Kernal Biopharma is backed by prominent venture capital firms and maintains a strong focus on developing globally competitive, high-quality therapeutics.